image

CONSISTENT EFFICACY

In 2 clinical trials that included procedures ranging from low to high bleeding risk.1

ADAPT‐1 and ADAPT‐2 were 2 identically designed, multicenter,
randomized, double‐blind, placebo‐controlled studies (N=435)1,2

Scroll left and right to view the full chart.
graphics

Primary endpoint:

Proportion of patients who did not require a platelet transfusion or any rescue procedure for bleeding after randomization and up to 7 days following an elective procedure.1

Secondary endpoint:

Proportion of patients who achieved platelet counts of ≥50x109/L on the day of procedure, and the change in platelet count from baseline to procedure day.1

  • Biliary interventions
  • Bronchoscopy +/- biopsy
  • Chemoembolization for HCC
  • Colonoscopy +/- polypectomy/biopsy
  • Dental procedures
  • Ethanol ablation
  • Laparoscopic interventions
  • Liver biopsy
  • Nephrostomy tube placement
  • Paracentesis
  • Radiofrequency ablation
  • Renal biopsy
  • Thoracentesis
  • Transjugular intrahepatic portosystemic shunt
  • Upper GI endoscopy +/- biopsy
  • Upper GI endoscopy +/- sclerotherapy
  • Upper GI endoscopy +/- variceal banding
  • Vascular catheterization

In the ADAPT studies, the percentage of patients who underwent procedures with low, moderate, or high risk was as follows: low, 60.8%; moderate, 17.2%; and high, 22.1%.2

Doptelet helps protect patients during and after a
scheduled procedure1

Doptelet significantly reduced the need for platelet transfusions or rescue procedures for bleeding for up to 7 days post procedure.1*

88%

of high-baseline patients taking Doptelet achieved the primary endpoint (N=117).1

66%

of low-baseline patients taking Doptelet achieved the primary endpoint (N=90).1

graphics

Mean platelet counts nearly doubled with Doptelet1

With Doptelet, platelet counts significantly increased by procedure day.1

Up to 45,000

in high-baseline patients

Up to 32,000

in low-baseline patients1

Scroll left and right to view the full chart.

 
 
picture

97% of patients whose platelet counts were measured on procedure day had an increase with Doptelet.1,3†

With Doptelet, patients can be ready for procedure day with ≥50,000 platelets/μL1

Significantly more patients achieved a platelet count of ≥50,000/μL with Doptelet.1

93%

of high-baseline patients reached the ≥50,000 platelets/μL target (N=58).1

69%

of low-baseline patients reached the ≥50,000 platelets/μL target (N=90).1

graphics

*From randomization of Doptelet 40 mg or Doptelet 60 mg once daily for 5 days up to 7 days after a procedure compared to placebo (P<0.0001; N=435).1

†270/277 patients treated with Doptelet in ADAPT-1 and ADAPT-2 had increased platelet counts by procedure day.1,3

PC=platelet count; qd=every day.

Looking into Doptelet safety data?

Here’s what was observed in clinical trials.

VIEW safety 

  1. DOPTELET (avatrombopag) [prescribing information]. Morrisville, NC: AkaRx, Inc;2025.
  2. Terrault N, Chen Y, Izumi N, et al. Avatrombopag before procedures reduces needs for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018;155(3):718.
  3. Data on file. The SAS System. 2023: Sobi, Inc.